Cesium-131 Brachytherapy May Be Prostate Cancer Game-changer, Study Reports

Cesium-131 Brachytherapy May Be Prostate Cancer Game-changer, Study Reports
About 161,360 new cases of prostate cancer will be diagnosed in the United States in 2017, according to the American Cancer Society. The usual treatment options are radiation or surgery, both of which are costly. A new brachytherapy isotope, Cesium-131, could be a game-changer, a study indicates. Brachytherapy involves placing radioactive implants, or seeds, directly onto tumors to destroy cancer cells while limiting damage to healthy tissue. IsoRay Medical markets Cesium-131 brachytherapy seeds. It is not only more cost-effective than other treatments, but also generates fewer sid
Subscribe or to access all post and page content.


  1. Jim Bidwell says:

    Can this treatment be used if patient has had radiation seed implants in 2009? My cancer has returned and is now hormone resistant. I am on Xtendi.

  2. Unfortunately Ms. Henriques incorrectly called Cs-131seeds, Gammatile.

    Cs-131 seeds are used in treating many cancers including: prostate, brain, head and neck, gyn, lung and others. They are not called Gammatile(s). For more information on cancer treatments using Cs-13, and physician and patient experiences, please see the Isoray website at isoray.com

    • Grace Frank says:

      An earlier version of this story wrongly reported that IsoRay Medical markets Cesium-131 brachytherapy seeds that it developed as GammaTile. GammaTile is under development by GT Medical Technologies.

Leave a Comment

Your email address will not be published. Required fields are marked *